Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

250.91
+2.130.86%
Pre-market: 252.841.93+0.77%04:25 EDT
Volume:3.87M
Turnover:967.41M
Market Cap:443.45B
PE:70.88
High:251.18
Open:247.73
Low:246.77
Close:248.78
52wk High:267.47
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.91
T/O Rate:0.22%
Dividend:6.83
Dividend Rate:2.72%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-74.72
PE(LYR):106.32

Loading ...

Abbvie Exec Says Strong Balance Sheet and Long Growth Runway Allow Company to Consider Both Early- and Late-Stage Business Development Opportunities - Conf Call

THOMSON REUTERS
·
Yesterday

Abbvie Exec Says Expects Approval of Subcutaneous Crohn's Disease Treatment in Q4 - Conf Call

THOMSON REUTERS
·
Yesterday

Movement Alert|AbbVie Falls 3.13% in Regular Trading, Trading at $248.79

Market Focus
·
Yesterday

Headlands Research Names Brandon Pallott Chief Commercial Officer

Reuters
·
Yesterday

BofA Securities Adjusts Price Target on AbbVie to $282 From $276

MT Newswires Live
·
Sep 08

AbbVie price target raised to $282 from $276 at BofA

TIPRANKS
·
Sep 08

Plastic Surgery is Booming with Boomers. Here's How to Cash in on the Antiaging Craze.

Dow Jones
·
Sep 08

Abbvie : Bofa Global Research Raises Price Objective to $282.00 from $276.00

THOMSON REUTERS
·
Sep 08

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Royalty Pharma (RPRX) and Summit Therapeutics (SMMT)

TIPRANKS
·
Sep 08

U.S. Research Roundup-Fedex Freight Holding Company, PDF Solutions, Robinhood Markets

Reuters
·
Sep 08

Plastic Surgery is Booming with Boomers. Here's How to Cash in on the Antiaging Craze.

Dow Jones
·
Sep 05

AbbVie Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 05

Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbbVie (ABBV)

TIPRANKS
·
Sep 04

Scotiabank Remains a Buy on AbbVie (ABBV)

TIPRANKS
·
Sep 04

AbbVie Closes $10.9B Apogee Deal — Accretion Not Until 2032

Bellwether Stocks Movement
·
Sep 04

AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032

Stock News
·
Sep 04

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
Sep 04

AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live
·
Sep 03

AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study

Dow Jones
·
Sep 03

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

TIPRANKS
·
Sep 03